Trial Profile
A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Temsirolimus (Primary) ; Vemurafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 01 Jun 2020 Status changed from active, no longer recruiting to completed.
- 21 Jan 2020 Planned End Date changed from 1 Dec 2020 to 31 Dec 2020.
- 21 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2020.